Sensyne Health (#SENS) – financing amendments, proposed delisting
- 2022-04-19 07:49:05
Sleazy Labour peer, Lord Drayson, pocketed an £850,000 bonus for floating Sensyne (SENS) at 175p, despite promising the Nomad he would not be so greedy. Now, three and a half years later, it has all gone horribly Pete Tong. So, will he hand the cash back, as those who backed the IPO prepare to lose, more or less, everything? Today, Drayson has got the order of the boot, and, to survive, shareholders face dilution to high heaven, while the shares will be slung off AIM.
He took an £850,000 bonus for staging the AIM IPO of Sensyne (SENS) even though he had promised his Nomad which had then assured institutional investors, that he would not. Then Lord Drayson used more company funds to pay off a whistleblower. This man, enobled by the war criminal Sir Tony Blair after, in a wholly unrelated way, donating vast sums to New Labour, is a festering wart on the backside of the corporate world. One hopes that a cash crisis will deal with this wart once and for all. Natch I have been a bear of this stock all along, unlike hedgie Matthew Scarborough of Gatemore who did his darndest to get me to pump this stock days before the scale of the current crisis started to become apparent.
It is not just sleazy Tory Lords that this website finds unacceptable, and I am not finished with cash for questions scumbag, the Earl of Shrewsbury yet. On the other side of the house sits Lord Drayson, a man enobled by the war criminal Blair and, by pure coincidence, a generous donor the the Labour party. Drayson founded and is CEO of Sensyne (SENS). And today there is another kick in the gonads for his shareholders.
Scumbag Labour Lord Drayson has today stated that the market fails to value his Sensyne (SENS) company and that as a result the company is enterimg a formal sales process as he tries to secure funding. So why might the market “undervalue” this company? Take your pick from these reasons.
On 17 September a chap called Matthew Scarborough subscribed to ShareProphets and at once sent us an email saying that he had an article he had drafted and wondered who he might submit it to for consideration. Hell: he might have had something interesting to say, some fraud to bust, so I suggested sending it to me. I had no idea who Mr Scarborough was. That could wait until I saw the piece.
A “settles employment tribunal claim” announcement from “clinical AI technology company”, Sensyne Health (SENS) including “as previously announced, Lorimer Headley, left the Board and the business on 2 March 2020. He made allegations against the CEO, Lord Drayson. The Board arranged for these allegations to be investigated by an independent law firm and they found that the allegations were not supported by the evidence”. So a favourable settlement for Lord Drayson and Sensyne then, surely?...
AIM-listed Sensyne Health (SENS) was spun out of Drayson Technologies and joined the Casino last August, raising £60 million in the process and has just published its first set of accounts as a listed company. No doubt Neil Woodford will have enjoyed the market response as the shares put on 7% (Woodford holds 20%), although not enough to extinguish his pain at Utilitywise (UTW) as the latter announced the dreaded “strategic review”. I doubt he will have enjoyed Sensyne’s ride as a plc either, as the IPO was at 175p per share and even after this rise the shares are 167p. Hardly a cracking endorsement! So what does Sensyne do? Well, it is – of course – disrupting its world! According to Woodford:
Turning to my third, and the most recent, quoted constituent of Woodford Patient Capital Trust (WPCT) this weekend, I thought I should give a warm welcome to Sensyne Health (SENS) that joined AIM on Friday at a very nice valuation indeed. It’s good to see that the words ‘healthtech’ and ‘AI’ are able to suck in as much dumb money from the markets these days as the word ‘blockchain’!







